Bayer’s higher dose aflibercept 8 mg with extended treatment intervals is set for approval in the European Union (EU) for neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DME).
Read More
FDA updates warning for contaminated eyedrop products
The US Food and Drug Administration (FDA) has issued product warnings for an additional 27 over-the-counter eyedrop products due to the potential risk of eye infections that could result in partial vision loss or blindness.
Read More
Read More
FDA clears higher dose Eylea; approvals sought in other markets
The US FDA has approved the use of high dose Eylea (aflibercept) for three macular conditions, equating to longer intravitreal injection intervals for patients.
Read More
Read More
FDA approves Iveric Bio’s IZERVAY for geographic atrophy
The US Food and Drug Administration (FDA) has approved a second therapy for geographic atrophy (GA), with IZERVAY (avacincaptad pegol intravitreal solution) by Iveric Bio given clearance with its new complement C5 inhibitor.
Read More
Read More
FDA approves Apellis’ SYFOVRE for first geographic atrophy treatment
In a historic first, the US Food and Drug Administration (FDA) has approved SYFOVRE (pegcetacoplan injection), manufactured by global biopharmaceutical company Apellis Pharmaceuticals, for geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Read More
Read More